Novo Nordisk has filed a U.S. federal lawsuit against Eli Lilly, alleging the company used false and deceptive advertising to promote its weight-loss drugs [1, 2].
The legal battle highlights the intensifying competition between the two pharmaceutical giants as they fight for dominance in the lucrative GLP-1 receptor agonist market. Because these medications have seen a massive surge in global demand, the accuracy of comparative efficacy claims is now a central point of corporate conflict.
Novo Nordisk alleges that Eli Lilly’s advertising for Zepbound and Mounjaro falsely suggests these products outperform Novo’s own offerings, Wegovy and Ozempic [1, 2]. The lawsuit claims that Lilly engaged in a nationwide pattern of deceptive advertising designed to confuse the public and cast Novo’s medicines in a poor light [3].
John Kuckelman, Novo Nordisk Group General Counsel and Senior Vice President, said the ads are deceiving customers [4]. According to the legal filing, the campaigns violate both federal and state advertising laws by misrepresenting the clinical superiority of Lilly's products [2, 3].
Eli Lilly has rejected the accusations. A company spokesperson said their ads are truthful and transparent, and they will defend them vigorously [4].
The dispute focuses on how pharmaceutical companies communicate clinical data to consumers. While both companies produce highly effective obesity treatments, Novo Nordisk argues that the marketing materials cross the line from competitive promotion into deliberate misinformation [2, 3].
“The ads are deceiving customers.”
This litigation signals a shift from scientific competition to legal warfare in the obesity drug market. As the industry matures, companies are moving beyond R&D to protect market share through aggressive litigation over 'comparative claims.' The outcome of this case could set a legal precedent for how pharmaceutical companies are allowed to compare their clinical trial results against competitors in consumer-facing advertisements.
